296 related articles for article (PubMed ID: 19898827)
1. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up.
Ehrlich R; Ciulla TA; Moss AM; Harris A
Graefes Arch Clin Exp Ophthalmol; 2010 Mar; 248(3):375-80. PubMed ID: 19898827
[TBL] [Abstract][Full Text] [Related]
2. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion.
Kim JY; Park SP
Korean J Ophthalmol; 2009 Dec; 23(4):259-65. PubMed ID: 20046685
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion.
Byun YJ; Roh MI; Lee SC; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):963-71. PubMed ID: 20182882
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion.
Shroff D; Bhargava A; Sharma B; Gupta C; Shroff C
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1203. PubMed ID: 20336307
[No Abstract] [Full Text] [Related]
7. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
Acta Ophthalmol; 2014 Nov; 92(7):e530-9. PubMed ID: 24373344
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combined intravitreal bevacizumab and triamcinolone for branch retinal vein occlusion.
Ali RI; Kapoor KG; Khan AN; Gibran SK
Indian J Ophthalmol; 2014 Apr; 62(4):396-9. PubMed ID: 24178408
[TBL] [Abstract][Full Text] [Related]
9. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
10. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion.
Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
Graefes Arch Clin Exp Ophthalmol; 2012 Aug; 250(8):1149-60. PubMed ID: 22331147
[TBL] [Abstract][Full Text] [Related]
11. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
Patel PJ; Zaheer I; Karia N
Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
[TBL] [Abstract][Full Text] [Related]
14. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
15. Changes in aqueous cytokines after intravitreal triamcinolone versus bevacizumab for macular oedema in branch retinal vein occlusion.
Sohn HJ; Han DH; Lee DY; Nam DH
Acta Ophthalmol; 2014 May; 92(3):e217-24. PubMed ID: 23889803
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.
Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
Gokce G; Sobaci G; Durukan AH; Erdurman FC
Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
